Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro

Stem Cell Research and Therapy

Volumn 8, Issue 1, 2017, Pages

  Redondo Castro, Elena ^a   Cunningham, Catriona ^a   Miller, Jonjo ^a   Martuscelli, Licia ^a   Aoulad Ali, Sarah ^a   Rothwell, Nancy J ^a   Kielty, Cay M ^a,b   Allan, Stuart M ^a   Pinteaux, Emmanuel ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bone marrow derived stromal cells; Cytokines; Human mesenchymal stem cells; Interleukin 1; Priming; Stroke

Indexed keywords

AUTACOID; BACTERIUM LIPOPOLYSACCHARIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; NERVE GROWTH FACTOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; LIPOPOLYSACCHARIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL IMMORTALIZATION; CONDITIONED MEDIUM; CONTROLLED STUDY; CYTOKINE RELEASE; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MICROGLIAL CELL CULTURE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SECRETION; SUPERNATANT; ADULT; ANIMAL; CYTOLOGY; DRUG EFFECTS; FEMALE; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MICROGLIA; MOUSE; PHARMACOLOGY; YOUNG ADULT;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; CULTURE MEDIA, CONDITIONED; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICROGLIA; NERVE GROWTH FACTORS; PHENOTYPE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85018475442     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-017-0531-4     Document Type: Article

References (62)

1. Giordano A, Galderisi U. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol. 2006;211:27-35.
2. Bang OY, Lee JS, Lee PH, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57(6):874-82.
3. Muñoz-Elias G, Woodbury D, Black I. Marrow stromal cells, mitosis, and neuronal differentiation: stem cell and precursor functions. Stem Cells. 2003;21:437-48.
4. Pittenger MF. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-7.
5. Reagan MR, Kaplan DL. Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells. 2011;29(6):920-7.
6. Le Blanc K, Pittenger MF. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36-45.
7. Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 2004;18(9):998-1000.
8. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-5.
9. Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32(4):1005-11.
10. Kalladka D, Muir KW. Brain repair: cell therapy in stroke. Stem Cells Cloning. 2014;7:31-44.
11. Torres-Espín A, Hernández J, Navarro X. Gene expression changes in the injured spinal cord following transplantation of mesenchymal stem cells or olfactory ensheathing cells. PLoS ONE. 2013;8(10):e76141.
12. Joyce N, Annett G, Wirthlin L, et al. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med. 2011;5(6):933-46.
13. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559.
14. Chen M, Li X, Zhang X, et al. The inhibitory effect of mesenchymal stem cell on blood-brain barrier disruption following intracerebral hemorrhage in rats: contribution of TSG-6. J Neuroinflamm. 2015;12(1):1-14.
15. Boido M, Piras A, Valsecchi V, et al. Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis. Cytotherapy. 2014;16(8):1059-72.
16. Kim S, Chang K-A, Kim JA, et al. The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer's disease mice. PLoS ONE. 2012;7(9):e45757.
17. Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy. Curr Opin Oncol. 2007;19(6):650-5.
18. Tobin MK, Bonds JA, Minshall RD, et al. Neurogenesis and inflammation after ischemic stroke: what is known and where we go from here. J Cereb Blood Flow Metab. 2014;34(10):1573-84.
19. Borsini A, Zunszain PA, Thuret S, et al. The role of inflammatory cytokines as key modulators of neurogenesis. Trends Neurosci. 2014;38(3):145-57.
20. Reardon S. A world of chronic disease. Science. 2011;333(6042):558-9.
21. Donnan GA, Fisher M, Macleod M, et al. Stroke Lancet. 2008;371(9624):1612-23.
22. George PM, Steinberg GK. Novel stroke therapeutics: unraveling stroke pathophysiology and its impact on clinical treatments. Neuron. 2015;87(2):297-309.
23. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 2006;66(3):232-45.
24. Xiao J, Nan Z, Motooka Y, et al. Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. Stem Cells Dev. 2005;14(6):722-33.
25. Kurozumi K, Nakamura K, Tamiya T, et al. BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol Ther. 2004;9(2):189-97.
26. Kim SJ, Moon GJ, Chang WH, et al. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. Trials. 2013;14(1):1.
27. Li Q, Wang Y, Deng Z. Pre-conditioned mesenchymal stem cells: a better way for cell-based therapy. Stem Cell Res Ther. 2013;4(3):1.
28. Trento C, Dazzi F. Mesenchymal stem cells and innate tolerance: biology and clinical applications. Swiss Med Wkly. 2010. doi: 10.4414/smw.2010.13121.
29. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.
30. Qian J, Zhu L, Li Q, et al. Interleukin-1R3 mediates interleukin-1-induced potassium current increase through fast activation of Akt kinase. Proc Natl Acad Sci U S A. 2012;109(30):12189-94.
31. Welte K. Discovery of G-CSF and Early Clinical Studies. Twenty Years of G-CSF. Basel: Springer Basel; 2012. p. 15-24.
32. Diederich K, Sevimli S, Dörr H, et al. The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: a characterization of G-CSF-deficient mice. J Neurosci. 2009;29(37):11572-81.
33. Kirsch F, Krüger C, Schneider A. The receptor for granulocyte-colony stimulating factor (G-CSF) is expressed in radial glia during development of the nervous system. BMC Dev Biol. 2008;8(32):32.
34. Schneider A, Krüger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005;115(8):2083-98.
35. Cui L, Duchamp NS, Boston DJ, et al. NF-κB is involved in brain repair by stem cell factor and granulocyte-colony stimulating factor in chronic stroke. Exp Neurol. 2015;263:17-27.
36. Komine-Kobayashi M, Zhang N, Liu M, et al. Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab. 2006;26(3):402-13.
37. Schäbitz W, Kollmar R, Schwaninger M, et al. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke. 2003;34(3):745-51.
38. Zhao L-RL, Singhal S, Duan WW-M, et al. Brain repair by hematopoietic growth factors in a rat model of stroke. Stroke. 2007;38(9):2584-91.
39. Sehara Y, Hayashi T, Deguchi K, et al. Potentiation of neurogenesis and angiogenesis by G-CSF after focal cerebral ischemia in rats. Brain Res. 2007;1151:142-9.
40. Kawada H, Fujita J, Kinjo K, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood. 2013;104(12):3581-7.
41. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7(4):430-6.
42. Park H-K, Chu K, Lee S-T, et al. Granulocyte colony-stimulating factor induces sensorimotor recovery in intracerebral hemorrhage. Brain Res. 2005;1041(2):125-31.
43. Diederich K, Quennet V, Bauer H, et al. Successful regeneration after experimental stroke by granulocyte-colony stimulating factor is not further enhanced by constraint-induced movement therapy either in concurrent or in sequential combination therapy. Stroke. 2012;43(1):185-92.
44. Mantovani A, Biswas SK, Galdiero MR, et al. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229(2):176-85.
45. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23-35.
46. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677-86.
47. Mantovani A, Locati M, Vecchi A, et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 2001;22(6):328-36.
48. England TJ, Sprigg N, Alasheev AM, et al. Granulocyte-colony stimulating factor (G-CSF) for stroke: an individual patient data meta-analysis. Sci Rep. 2016. doi: 10.1038/srep36567.
49. Kallmünzer B, Tauchi M, Schlachetzki JC, et al. Granulocyte colony-stimulating factor does not promote neurogenesis after experimental intracerebral haemorrhage. Int J Stroke. 2014;9(6):783-8.
50. Diederich K, Schmidt A, Beuker C, et al. Granulocyte colony-stimulating factor (G-CSF) treatment in combination with transplantation of bone marrow cells is not superior to G-CSF treatment alone after cortical stroke in spontaneously hypertensive rats. Front Cell Neurosci. 2014;8:1-9.
51. Ringelstein EB, Thijs V, Norrving B, et al. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013;44(10):2681-7.
52. Schäbitz WR, Laage R, Vogt G, et al. AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke. 2010;41(11):2545-51.
53. Emsley HC a, Smith CJ, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76(10):1366-72.
54. Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27-55.
55. Siddappa R, Licht R, Van Blitterswijk C, et al. Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res. 2007;25:1029-41.
56. Siegel G, Kluba T, Hermanutz-Klein U, et al. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013;11:146.
57. Montzka K, Lassonczyk N, Tschöke B, et al. Neural differentiation potential of human bone marrow-derived mesenchymal stromal cells: misleading marker gene expression. BMC Neurosci. 2009;10:16.
58. Portalska KJ, Groen N, Krenning G, et al. The effect of donor variation and senescence on endothelial differentiation of human mesenchymal stromal cells. Tissue Eng Part A. 2013;19(21-2):2318-29.
59. Huang S, Feng C, Wu Y, et al. Dissimilar characteristics of umbilical cord mesenchymal stem cells from donors of different ages. Cell Tissue Bank. 2013;14(4):707-13.
60. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A. 2007;104(26):11002-7.
61. Capra E, Beretta R, Parazzi V, et al. Changes in the proteomic profile of adipose tissue-derived mesenchymal stem cells during passages. Proteome Sci. 2012;10(1):46.
62. Czekanska EM, Ralphs JR, Alini M, et al. Enhancing inflammatory and chemotactic signals to regulate bone regeneration. Eur Cell Mater. 2014;28:320-34.